Meeting
2016 ASCO Annual Meeting
A phase 1 study of enoblituzumab in combination with pembrolizumab in patients with advanced B7-H3-expressing cancers.
Authors
Naiyer A. Rizvi
Columbia University Medical Center, New York, NY
Naiyer A. Rizvi , Deryk Loo , Jan E. Baughman , Soyoung Yun , Francine Chen , Paul A. Moore , Ezio Bonvini , James Robert Vasselli , Jon M. Wigginton , Roger B. Cohen , Charu Aggarwal , Anthony W. Tolcher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT02475213
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS3104)
DOI
10.1200/JCO.2016.34.15_suppl.TPS3104
Abstract #
TPS3104
Poster Bd #
421b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1 trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Philippe L. Bedard
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2023 ASCO Annual Meeting
ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.
First Author: Jie Wang